Raymond James & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Raymond James & Associates’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-43,000	Closed	-$1.81M	–	4002
2024 Q2	$1.81M	Buy	+43,000	New	+$1.92M	﹤0.01%	2225
2024 Q1	–	Sell	-7,500	Closed	-$413K	–	3928
2023 Q4	$413K	Buy	+7,500	New	+$394K	﹤0.01%	3072
2023 Q1	–	Sell	-20,300	Closed	-$20.9K	–	3891
2022 Q4	$20.9K	Buy	+20,300	New	+$1.53M	﹤0.01%	3792
2022 Q2	–	Sell	-10,800	Closed	-$50K	–	4040
2022 Q1	$50K	Sell	10,800 -80,300	-88%	-$5.39M	﹤0.01%	3911
2021 Q4	$122K	Buy	91,100 +9,200	+11%	+$540K	﹤0.01%	3829
2021 Q3	$37K	Buy	81,900 +2,000	+3%	+$132K	﹤0.01%	3943
2021 Q2	$73K	Buy	79,900 +53,400	+202%	+$3.48M	﹤0.01%	3878
2021 Q1	$49K	Buy	26,500 +3,900	+17%	+$243K	﹤0.01%	3856
2020 Q4	$7K	Buy	+22,600	New	+$1.39M	﹤0.01%	3733
2019 Q4	–	Sell	-56,000	Closed	-$55K	–	3672
2019 Q3	$55K	Buy	+56,000	New	+$2.63M	﹤0.01%	3457
2017 Q1	–	Sell	-13,600	Closed	-$49K	–	3302
2016 Q4	$49K	Sell	13,600 -39,700	-74%	-$2.17M	﹤0.01%	3096
2016 Q3	$9K	Sell	53,300 -11,100	-17%	-$713K	﹤0.01%	3172
2016 Q2	$128K	Buy	64,400 +17,100	+36%	+$1.21M	﹤0.01%	2759
2016 Q1	$19K	Buy	+47,300	New	+$2.98M	﹤0.01%	2861

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates's BMY Position: Q3 2024 in Review

Raymond James & Associates increased its Bristol-Myers Squibb (BMY) stake by 0.9% in Q3 2024, buying an estimated $1.34M and bringing the position to 3,215,555 shares worth $166M. The position accounts for 0.1% of the portfolio, ranked #175.

Raymond James & Associates first reported a position in BMY in Q2 2013 and has held it in 46 quarters since. The position peaked at $275M in Q1 2022. 2,259 funds tracked by Wall St. Rank hold BMY as of Q3 2024.

Raymond James & Associates held 3,215,555 shares of Bristol-Myers Squibb worth $166M as of Q3 2024.
Raymond James & Associates bought 28,528 Bristol-Myers Squibb shares in Q3 2024, an estimated $1.34M.
Bristol-Myers Squibb made up 0.1% of Raymond James & Associates's portfolio in Q3 2024, its #175 holding.
Raymond James & Associates first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 46 quarters since.
Raymond James & Associates's Bristol-Myers Squibb position peaked at $275M in Q1 2022.
2,259 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.